Eton Pharma fails to win USFDA nod for conjunctivitis treatment

The company sold the U.S. rights to its EM-100 eye drop for treating itching associated with allergic conjunctivitis to Bausch Health Companies Inc in February.

New Delhi: Eton Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration declined to approve its treatment for conjunctivitis, sending its shares tumbling nearly 20 percent in extended trading.

No concerns were raised about the clinical data in the application, and the company expects to respond to the FDA’s complete response letter shortly, Eton said, without providing more detail.

Eton also said it does not expect any additional clinical work would be required for the approval of the treatment.

“We believe the issues cited in the complete response letter can be addressed in the coming months,” Chief Executive Officer Sean Brynjelsen said.

The company sold the U.S. rights to its EM-100 eye drop for treating itching associated with allergic conjunctivitis to Bausch Health Companies Inc in February, reports Reuters.

Eton is primarily focused on liquid dosage forms including injectables, oral liquids, and ophthalmics. The pharma company has a diversified pipeline of high-value product candidates in various stages of development and therapeutic areas, including multiple product candidates currently pending regulatory approval with the FDA.

Read Also: Elizabeth Warren asks former USFDA chief Gottlieb to QUIT Pfizer board